Rhyme (mRNA-1365-P101)
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to 24 months.
Rationalise
There is no existing approved vaccine or specific therapy for RSV or hMPV infection. ALRI associated with these viruses remains a large and significant unmet medical need in the paediatric population globally. Given high burdens of disease in infants and young children, similar disease presentations, and comparable viral circulation patterns, a multi-component (combination) vaccine against RSV and hMPV would provide broader protection and even greater public health benefit than would a vaccine against either virus alone.
Investigators
- Dr Jeanne Coetzee, Principal Investigator
- Dr Faeezah Patel, Sub-Investigator
- Dr Elizea Horne, Sub-Investigator
- Prof Lee Fairlie, Sub-Investigator
- Dr Mrinmayee Dhar, Sub-Investigator
- Dr Muneerah Khan, Sub-Investigator
- Tiffany Seef, Clinical Associate
- Othusitse Segalo, Clinical Associate
Latest Update
March 2024
For more details about Rhyme (mRNA) Study please email rhicomms@wrhi.ac.za
